Cargando…

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia

Abnormal iron accumulation in vital organs is one of the major complications of β‐thalassemia intermedia (β‐TI). Silymarin, a flavonolignan isolated from Silybum marianum, significantly decreases the serum ferritin levels of β‐TI patients. This finding suggests silymarin as a safe and effective natu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reisi, Nahid, Esmaeil, Nafiseh, Gharagozloo, Marjan, Moayedi, Behjat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784915/ https://www.ncbi.nlm.nih.gov/pubmed/35106163 http://dx.doi.org/10.1002/ccr3.5293

Ejemplares similares

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

Protective Role of Silymarin and Deferoxamine Against Iron Dextran-induced Renal Iron Deposition in Male Rats
por: Nematbakhsh, Mehdi, et al.
Publicado: (2013)

Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model
por: Navidi-Shishaone, Mitra, et al.
Publicado: (2014)

Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
por: Schmidt, Paul J, et al.
Publicado: (2015)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Endocrine Function in Thalassemia Intermedia
por: Karamifar, H., et al.
Publicado: (2006)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
por: Nuzzi, Raffaele, et al.
Publicado: (2021)

CMR survey in Thalassemia Intermedia patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Re: “Protective Role of Silymarin and Deferoxamine against Iron Dextran-Induced Renal Iron Deposition in Male Rats,” and “Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model”
por: Mazaheri, Safoora, et al.
Publicado: (2014)

Did the Proband Have Thalassemia Intermedia or Severe Thalassemia Trait?
por: Özsoylu, Şinasi
Publicado: (2012)

Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea
por: Zekavat, Omid Reza, et al.
Publicado: (2014)

β-Thalassemia Intermedia: A Bird’s-Eye View
por: Haddad, Anthony, et al.
Publicado: (2014)

Iron homeostasis in a mouse model of thalassemia intermedia is altered between adolescence and adulthood
por: Sanyear, Chanita, et al.
Publicado: (2020)

P1454: CLINICAL DETERMINANTS OF CARDIAC IRON IN REGULARLY TRANSFUSED THALASSEMIA INTERMEDIA PATIENTS
por: Meloni, Antonella, et al.
Publicado: (2023)

Evaluation of Cardiac Function in Patients with Thalassemia Intermedia
por: Nouri, NM, et al.
Publicado: (2013)

Secondary Haemochromatosis in a Patient with Thalassemia Intermedia
por: ROTARU, IONELA, et al.
Publicado: (2014)

Protein C and S levels in patients with Thalassemia intermedia
por: Mohammed, Nawsherwan Sadiq
Publicado: (2022)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

β-Thalassemia Intermedia: Interaction of α-Globin Gene Triplication With β-thalassemia Heterozygous in Spain
por: Ropero, Paloma, et al.
Publicado: (2022)

The Link of Pancreatic Iron with Glucose Metabolism and Cardiac Iron in Thalassemia Intermedia: A Large, Multicenter Observational Study
por: Meloni, Antonella, et al.
Publicado: (2021)

Molecular characterization of β-thalassemia intermedia in the West Bank, Palestine
por: Faraon, Rashail, et al.
Publicado: (2019)

Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial
por: Al-Momen, Hayder, et al.
Publicado: (2020)

Harnessing microbial iron chelators to develop innovative therapeutic agents
por: Ribeiro, Marta, et al.
Publicado: (2021)

Echocardiographic evaluation of thalassemia intermedia patients in Duhok, Iraq
por: Mohammad, Ameen Mosa
Publicado: (2014)

Tophaceous gout in thalassemia intermedia: a rare association
por: Mishra, Vikas, et al.
Publicado: (2016)

Gaucher-like Cells in Thalassemia Intermedia: Is It a Challenge?
por: Komninaka, Veroniki, et al.
Publicado: (2023)

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy
por: Zarghamian, Parinaz, et al.
Publicado: (2020)

Silymarin Dehydroflavonolignans Chelate Zinc and Partially Inhibit Alcohol Dehydrogenase
por: Tvrdý, Václav, et al.
Publicado: (2021)

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major
por: Khezri, Hadi Darvishi, et al.
Publicado: (2016)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

β-Thalassemia Intermedia in Northern Iraq: A Single Center Experience
por: Al-Allawi, Nasir A. S., et al.
Publicado: (2014)

Cyclic headaches in β-thalassemia intermedia case presenting as moyamoya syndrome
por: Akpınar, Süha, et al.
Publicado: (2015)

Endocrine and Bone Complications in β-Thalassemia Intermedia: Current Understanding and Treatment
por: Inati, Adlette, et al.
Publicado: (2015)

Three Mexican Families with β thalassemia intermedia with different molecular basis
por: de la Torre, Lourdes del Carmen Rizo, et al.
Publicado: (2020)

Renal Dysfunction in Pediatric Patients in Iraq With β-Thalassemia Major and Intermedia
por: Shaalan, Mohammad G, et al.
Publicado: (2022)

Stroke propensity in the Th3+/ mouse model of β-thalassemia intermedia
por: Sun, Yu-Yo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1k1abura7vvkl4o8somndup7t